Audeo is a late-stage, oncology focused biopharmaceutical company with an integrated pipeline of products stemming from two core technology platforms
VAST is an innovative small molecule discovery platform with unique 3D compound shapes that expand chemical diversity.
Alchemia has a marketed product and a late stage oncology pipeline.
Audeo Oncology is a wholly owned subsidiary of Alchemia, established to capitalise on HA-Irinotecan.
In-licensing of novel FAK Inhibitors
Listen to CEO presentation at Cowen conference